ILUMYA (tildrakizumab-asmn) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.
The drug was developed by Schering-Plough, which merged with US-based drug maker Merck & Co in 2009. Sun Pharma acquired worldwide rights for ILUMYA from Merck & Co for $80m.
Sun Pharmaceuticals’ biologics license application (BLA) for ILUMYA was accepted for review by the US Food and Drug Administration (FDA) in May 2017 and approved in March 2018.
In June 2016, Sun Pharma signed a licensing agreement with Spain’s Almirall to market ILUMYA in Europe. Almirall completed the regulatory filing for ILUMYA with the European Medicines Agency (EMA) in March 2017.
In September 2018, ILUMYA received approvals from the European Commission (EC)and Therapeutic Goods Administration (TGA) for marketing in Europe and Australia respectively.
Plaque psoriasis is an autoimmune inflammatory disorder triggered by infections and stress. It is the most common form of the disease, diagnosed in more than 80% of psoriasis cases.
The most common symptom of the infection is a rash on the skin, nails or joints. The infection appears as red, raised areas of skin covered with flaky white scales, which may be itchy and painful. The scales can crack and bleed when the infection is severe.
Topical treatments, light therapy and systemic medications can help to reduce inflammation.
The disease affects approximately 125 million people worldwide and more than 7.5 million people in the US alone.
ILUMYA’s principal ingredient Tildrakizumab is a humanised IgG1 / k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and prevents its interaction with the IL-23 receptor.
The process prevents the release of pro-inflammatory cytokines and chemokines, responsible for the inflammatory and immune responses known to occur in plaque psoriasis.
The drug is administered as a subcutaneous injection and is available in the form of a pre-filled syringe containing 100mg / ml of tildrakizumab-asmn.
FDA approval for ILUMYA comes from data of Phase III clinical development programme reSURFACE, which included multi-centre, randomised, placebo-controlled trials reSURFACE 1 and reSURFACE 2.
The safety and efficacy of the drug in both trials were measured through a psoriasis area sensitivity index (PASI) score, measuring redness, scaling and thickness.
The efficacy of the drug against plaque psoriasis was also measured using a physician’s global assessment (PGA) score, which measures thickness, erythema and scaling of the patient’s psoriasis lesions.
A total of 926 patients enrolled in the studies. Of these, 69% were male and 80% Caucasian, with a median age of 46 years.
Of those enrolled, 616 patients were randomised to receive ILUMYA, while the remaining 310 participants were administered with placebo at weeks zero and four, as well as every 12 weeks afterwards.
Both studies achieved the primary endpoint of at least 75% of skin clearance as measured by PASI and PGA scores. In the reSURFACE 1 study, 74% of patients achieved 75% skin clearance at week 28.
The most common adverse reactions associated with the use of ILUMYA were upper respiratory tract infections and diarrhoea. The drug may also cause severe allergic reactions such as throat and chest tightness, swelling of the face and lips and skin rash.
Sun Pharma is an India-based clinical-stage biopharmaceutical company focused on improving standards of care for patients through innovation in therapeutics.
The company has a global presence, with 41 manufacturing locations in six continents.
The company invests more than 8% of its annual revenue in research and development (R&D) activities.
WAKIX® (pitolisant) is the first and only non-scheduled medication indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS)…
SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody. It is indicated for the treatment…
Nucala® (mepolizumab) is the first biologic therapy indicated for the treatment of hypereosinophilic syndrome (HES) in adult and paediatric patients…
Gavreto™ (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung…